SCHEMBL318239

SCHEMBL318239

CCC(Br)(CC)C(N)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9640452 0.85 LMNA (0.38)
SCHEMBL4992703 0.78 LMNA (0.40)
SCHEMBL7806387 0.77
SCHEMBL32691462 0.74
SCHEMBL1831345 0.74
SCHEMBL4998321 0.74 FDPS (0.40)
SCHEMBL1553705 0.73
SCHEMBL1449044 0.73
SCHEMBL11466197 0.73
Carbromal SCHEMBL4351621 0.72 CRBN (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9770514-B2 Tamper-resistant pharmaceutical dosage forms ExxPharma Therapeutics LLC (US) 2017-09-26 US claimed
US-20150064250-A1 Tamper-Resistant Pharmaceutical Dosage Forms ExxPharma Therapeutics LLC (US) 2015-03-05 US claimed
US-7214381-B2 Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels ANTARES PHARMA IPL AG (CH) 2007-05-08 US claimed
US-20030199426-A1 Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels ANTARES PHARMA, INC. 2003-10-23 US claimed
CN-1122024-C Process for converting hydroxy heteroaromatic compounds to arylamines AVENTIS PHARMA INC (US) 2003-09-24 CN claimed
EP-1323431-A2 Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels Antares Pharma IPL AG (CH) 2003-07-02 EP claimed
EP-1307232-A1 NOVEL COMPOSITION FOR TRANSDERMAL AND/OR TRANSMUCOSAL ADMINISTRATION OF ACTIVE COMPOUNDS THAT ENSURES ADEQUATE THERAPEUTIC LEVELS Antares Pharma IPL AG (CH) 2003-05-07 EP claimed
WO-2002006826-B1 SINGLE-PATIENT DRUG TRIALS USED WITH ACCUMULATED DATABASE OPT E SCRIP INC (US) 2002-04-04 WO claimed
US-20020032581-A1 Single-patient drug trials used with accumulated database: risk of habituation OPT-E-SCRIP, INC. 2002-03-14 US claimed
WO-2002011768-A1 NOVEL COMPOSITION FOR TRANSDERMAL AND/OR TRANSMUCOSAL ADMINISTRATION OF ACTIVE COMPOUNDS THAT ENSURES ADEQUATE THERAPEUTIC LEVELS ANTARES PHARMA IPL AG (CH) 2002-02-14 WO claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
US-6034241-A Process for converting hydroxy heteroaromatics to arylamines HOECHST MARION ROUSSEL INC. (US) 2000-03-07 US claimed
CN-1238763-A Process for converting hydroxy heteroaromatics to arylamines HOECHST MARION ROUSSEL INC (US) 1999-12-15 CN claimed
EP-0944600-A1 PROCESS FOR CONVERTING HYDROXY HETEROAROMATICS TO ARYLAMINES HOECHST MARION ROUSSEL, INC. (US) 1999-09-29 EP claimed
CN-1222915-A Alkylation and Schmeis rearrangement of hydroxyaromatic compounds HOECHST MARION ROUSSEL INC (US) 1999-07-14 CN claimed
EP-0888380-A1 PROCESS FOR ALKYLATING AND SMILES REARRANGEMENT OF HYDROXY AROMATICS HOECHST MARION ROUSSEL, INC. (US) 1999-01-07 EP claimed
US-5817874-A Process for alkylating and smiles rearrangement of hydroxy aromatics HOECHST MARION ROUSSEL, INC. (US) 1998-10-06 US claimed
WO-1998023589-A1 PROCESS FOR CONVERTING HYDROXY HETEROAROMATICS TO ARYLAMINES HOECHST MARION ROUSSEL, INC. (US) 1998-06-04 WO claimed
WO-1997034916-A1 PROCESS FOR ALKYLATING AND SMILES REARRANGEMENT OF HYDROXY AROMATICS HOECHST MARION ROUSSEL, INC. (US) 1997-09-25 WO claimed
US-4805340-A Humane glue trap for rats, mice and other vermin having carbomal in the bait TAMBY CHEMICAL CORP. (US) 1989-02-21 US claimed